Evidence map›Paper›PMID 35874090›Full record

ArticleMaterials today. Proceedings2022

A critical review of an additive manufacturing role in Covid-19 epidemic.

Jinka Rupesh Kumar, K Mayandi, S Joe Patrick Gnanaraj, K Chandrasekar, P Sethu Ramalingam

Abstract read
In one paragraph

Article in Materials today. Proceedings, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jinka Rupesh KumarDepartment of Mechanical Engineering, Kalasalingam Academy of Research and Education, Krishnankoil, Tamilnadu, India.
K MayandiDepartment of Mechanical Engineering, Kalasalingam Academy of Research and Education, Krishnankoil, Tamilnadu, India.
S Joe Patrick GnanarajDepartment of Mechanical Engineering, St.Mother Theresa Engineering College, Tamilnadu, India.
K ChandrasekarDepartment of Mechanical Engineering, PSN College of Engineering and Technology, Tirunelveli, TamilNadu, India.
P Sethu RamalingamDepartment of Mechanical Engineering, Rajalakshmi Institute of Technology, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2019, a massive and deadly coronavirus pandemic known as the COVID-19 pandemic has swept through more than 180 nations, causing a massive strain on already overtaxed health systems around the globe. Global demand for medical equipment has put a strain on traditional manufacturing methods, resulting in the need for an efficient, low-cost, and speedy mode of production. Additive manufacturing, or 3D printing, has been used by manufacturers to bridge the gap and enhance the production of medical products. Some designs that had been previously or conventionally fabricated have been revised to meet the 3D printing requirement for combating COVID-19. A variety of designs were created, and they are now in use in hospitals by patients and healthcare professionals. However, because some gadgets must adhere to rigorous standards, it is possible that some items will not meet these requirements. As a result, in order to protect the health of the user, it is necessary to understand each gadget, its usage, and industry standards. An investigation of the usage of additive manufacturing during the COVID-19 epidemic is presented in this paper. It brings together the manufacturers of a variety of 3D-printed products, including face shields, face masks, valves, nasopharyngeal swabs, and others, to debate their application and regulatory concerns in the medical field. The primary shortcoming of technology, discussed in reference to the next pandemic, is addressed here. It also looks at some of the ways that additive manufacturing could be used in the future during an emergency.

Indexed as

3D printingAdditive ManufacturingCOVID −19Epidemic

Identifiers

PMID35874090
PMCPMC9289093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.